Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Multiple Myeloma
10m 19s
CAR -T cells in Lymphoma
Published 11 Jul 2022
CAR-T cell therapies are approved for treatment of Diffuse Large B Cell Lymphoma (DLBCL) , Follicular Lymphoma & Mantle Cell Lymphoma. CAR T-cell therapies namely axicabtagene ciloleucel, lisocabtagene maraleucel , tisagenlecleucel are approved for usage in Lymphoma. CAR-T cells have shown efficacy in later line treatment of Lymphoma. Individual CAR-T cell-based treatments have different neurotoxicity profile which is an important consideration in choosing right CAR-T cell treatment for individual patient.
